Futibatinib - an Irreversible FGFR1-4 Inhibitor for the Treatment of FGFR-Aberrant Tumors

Sep 24, 2026

Uploaded by Aran

Fibroblast growth factor receptors (FGFR) are emerging therapeutic targets in advanced, refractory cancers. Reversible FGFR inhibitors under investigation can be limited by acquired drug resistance. This review summarizes futibatinib’s preclinical and clinical development as an irreversible FGFR1-4 inhibitor, highlighting covalent binding with low susceptibility to resistance. Preclinical data show activity against FGFR kinase domain resistance mutations, and early trials report responses across multiple FGFR-aberrant tumor types.

LanguageEnglish

CategoryHealthcare

FormatPDF

Pages16

Reading Time40 min

AccessFree to download

Abstract

Implications for Practice

Introduction

FGFR as an Oncologic Target

Futibatinib, an Irreversible FGFR1-4 Inhibitor for the Treatment of FGFR-Aberrant Tumors Milind Javle1,*, Gentry King2, Kristen Spencer3,4,, Mitesh J. Borad5 1Department of Gastrointestinal Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, USA 2Division of Medical Oncology, University of Washington, Seattle, WA, USA 3 Perlmutter Cancer Center of NYU Langone Health, New York, NY, USA 4 NYU Grossman School of Medicine, New York University, New York, NY, USA 5Department of Oncology, Mayo Clinic Cancer Center, Phoenix, AZ,USA * Corresponding author: Milind Javle, MD, Department of Gastrointestinal Medical Oncology, MD Anderson Cancer Center, Houston, TX 77030, USA. Tel: +1 713 792 2828; [Email:](Email: mjavle@mdanderson.org)[ mjavle@mdanderson.org](Email: mjavle@mdanderson.org) Abstract Fibroblast growth factor receptors (FGFR) are emerging as an important therapeutic target for patients with advanced, refractory cancers . Most selective FGFR inhibitors under investigation show reversible binding, and their activity is limited by acquired drug resistance . This review summarizes the preclinical and clinical development of futibatinib, an irreversible FGFR1-4 inhibitor. Futibatinib stands out among FGFR inhibitors because of its covalent binding mechanism and low susceptibility to acquired resistance . Preclinical data indicated robust activity of futibatinib against acquired resistance mutations in the FGFR kinase domain. In early-phase studies, futibatinib showed activity incholangiocarcinoma, and gastric, urothelial, breast, central nervous system, and head and neck cancers harboring various FGFR aberrations. Exploratory analyses indicated clinical benefit with futibatinib after prior FGFR inhibitor use . In a pivotal phase II trial, futibatinib demonstrated durable objective responses (42% objective response rate) and tolerability in previously treated patients with advanced intrahepatic cholangiocarcinoma harboring FGFR2 fusions or rearrangements. A manageable safety profile was observed across studies, and patient quality of life was maintained with futibatinib treatment in patients with cholangiocarcinoma. Hyperphosphatemia, the most common adverse event with futibatinib, was well managed and did not lead to treatment discontinuation. These data show clinically meaningful benefit with futibatinib in FGFR2-rearrangement-positive cholangiocarcinoma and provide support for further investigation of futibatinib across other indications. Future directions for this agent include elucidating mechanisms of resistance and exploration of combination therapy approaches. Key words: fibroblast growth factor receptor; FGFR inhibitor; futibatinib; cholangiocarcinoma; safety; clinical trials. Implications for Practice Patients with FGFR-altered cancers have limited treatment options in advanced stages. Promising responses have been observed with FGFR inhibitors; however, acquired resistance is an emerging concern. This review summarizes data surrounding futibatinib, the only second-generation FGFR1-4 inhibitors in phase II/III clinical development. Futibatinib has shown durable efficacy and tolerability incholangiocarcinoma with FGFR2 fusions/rearrangements, and recently received approval from the US Food and Drug Administration for this indication. Futibatinib has demonstrated antitumor activity across several FGFR-aberrant tumors, spurring the initiation of several phase II trials of futibatinib or futibatinib-containing combinations in other tumor types. Introduction Fibroblast growth factors (FGFs) and their receptors (FGFRs) play an integral role in regulating a wide range of biological processes1 and dysregulation of the FGFR pathway is associated with oncogenesis.2-7 Approximately 7% of all cancers harbor FGFR aberrations, with type and prevalence varying widely.8 Thus, FGFR has emerged as an important therapeutic target. Most FGFR inhibitors in development are ATPcompetitive, reversible inh

FAQs

Why is futibatinib considered distinct among FGFR inhibitors?

Futibatinib is highlighted for its covalent (irreversible) binding mechanism, resulting in low susceptibility to acquired resistance compared with reversible FGFR inhibitors.

What clinical benefit did futibatinib show in cholangiocarcinoma?

A pivotal phase II trial reported durable objective responses (42% objective response rate) and tolerability in previously treated patients with advanced intrahepatic cholangiocarcinoma harboring FGFR2 fusions or rearrangements.

What safety concern is most common with futibatinib, and how was it handled?

Hyperphosphatemia is the most common adverse event and was described as well managed without leading to treatment discontinuation.

Sep 24, 2026

Uploaded by Aran